The diagnosis and classification of glioma by liquid biopsy represent a critical unmet need in neuro-oncology. A recent study demonstrates targeted next-generation sequencing of cell-free DNA from cerebrospinal fluid as an evolving option for liquid biopsy in patients with glioma.

See related article by Iser et al., p. 2974

©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.